These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18206703)

  • 21. Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? a mixed methods evaluation.
    Kato-Lin YC; Krishnamurti L; Padman R; Seltman HJ
    Int J Med Inform; 2014 Nov; 83(11):814-24. PubMed ID: 25179666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Derivation and preliminary validation of a risk score to predict 30-day ED revisits for sickle cell pain.
    Glassberg J; Simon J; Patel N; Jeong JM; McNamee JJ; Yu G
    Am J Emerg Med; 2015 Oct; 33(10):1396-401. PubMed ID: 26283616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of short-term emergency department observation care of children with sickle cell disease and vaso-occlusive crises: initial experience from south-western Nigeria.
    Adegoke SA; Oladimeji OI; Ologun BG; Aladekomo TA; Oyelami OA
    Trans R Soc Trop Med Hyg; 2020 May; 114(5):365-371. PubMed ID: 32181486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization.
    Binding A; Ward R; Phua C; Naessens V; O'Brien T; Bhatia S; Baranek H; Marani H; Mukerji G
    CJEM; 2019 Jan; 21(1):55-62. PubMed ID: 29039292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial.
    Lubega FA; DeSilva MS; Munube D; Nkwine R; Tumukunde J; Agaba PK; Nabukenya MT; Bulamba F; Luggya TS
    Scand J Pain; 2018 Jan; 18(1):19-27. PubMed ID: 29794277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to pain relief: A randomized controlled trial in the emergency department during vaso-occlusive episodes in sickle cell disease.
    Tanabe P; Bosworth HB; Crawford RD; Glassberg J; Miller CN; Paice JA; Silva S
    Eur J Haematol; 2023 May; 110(5):518-526. PubMed ID: 36602417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of an Emergency Department Observation Unit-Based Pathway for the Treatment of Uncomplicated Vaso-occlusive Events in Sickle Cell Disease.
    Lyon M; Sturgis L; Lottenberg R; Gibson ME; Eck J; Kutlar A; Gibson RW
    Ann Emerg Med; 2020 Sep; 76(3S):S12-S20. PubMed ID: 32928457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department.
    García-Morin M; López-Sangüos C; Vázquez P; Alvárez T; Marañón R; Huerta J; Cela E
    Hemoglobin; 2016 Nov; 40(6):388-391. PubMed ID: 28361592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between trauma triage and time-to-vaso-occlusive events in patients with sickle cell disease after traumatic injury: a retrospective study.
    Parchuri E; Pacella-LaBarbara M; O'Brien J; Gruen DS; Guyette F; Brown JB; De Castro L; Jonassaint CR
    Trauma Surg Acute Care Open; 2023; 8(1):e001200. PubMed ID: 38020866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Standardized Emergency Department Order Set Decreases Admission Rates and In-Patient Length of Stay for Adults Patients with Sickle Cell Disease.
    Wachnik AA; Welch-Coltrane JL; Adams MCB; Blumstein HA; Pariyadath M; Robinson SG; Saha A; Summers EC; Hurley RW
    Pain Med; 2022 Dec; 23(12):2050-2060. PubMed ID: 35708651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial.
    Rees CA; Brousseau DC; Cohen DM; Villella A; Dampier C; Brown K; Campbell A; Chumpitazi CE; Airewele G; Chang T; Denton C; Ellison A; Thompson A; Ahmad F; Bakshi N; Coleman KD; Leibovich S; Leake D; Hatabah D; Wilkinson H; Robinson M; Casper TC; Vichinsky E; Morris CR;
    Trials; 2023 Aug; 24(1):538. PubMed ID: 37587492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease.
    Harris EM; Vilk E; Donado C; Williams A; Heeney MM; Solodiuk J; Greco C; Archer NM
    Pediatr Blood Cancer; 2023 May; 70(5):e30254. PubMed ID: 36861789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective.
    Rees CA; Brousseau DC; Ahmad FA; Bennett J; Bhatt S; Bogie A; Brown KM; Casper TC; Chapman LL; Chumpitazi CE; Cohen DM; Dampier C; Ellison AM; Grasemann H; Hatabah D; Hickey RW; Hsu LL; Bakshi N; Leibovich S; Patil P; Powell EC; Richards R; Sarnaik S; Weiner DL; Morris CR;
    Am J Hematol; 2023 Apr; 98(4):620-627. PubMed ID: 36606705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pain management trend of vaso-occulsive crisis (VOC) at a community hospital emergency department (ED) for patients with sickle cell disease.
    Inoue S; Khan I; Mushtaq R; Sanikommu SR; Mbeumo C; LaChance J; Roebuck M
    Ann Hematol; 2016 Jan; 95(2):221-5. PubMed ID: 26611852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
    Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
    J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of an emergency department pain management protocol on the pattern of visits by patients with sickle cell disease.
    Givens M; Rutherford C; Joshi G; Delaney K
    J Emerg Med; 2007 Apr; 32(3):239-43. PubMed ID: 17394984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioid prescription practices at discharge and 30-day returns in children with sickle cell disease and pain.
    Okorji LM; Muntz DS; Liem RI
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27800652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the effect of patient-specific versus weight-based protocols to treat vaso-occlusive episodes in the emergency department.
    Tanabe P; Ibemere S; Pierce AE; Freiermuth CE; Bosworth HB; Yang H; Osunkwo I; Paxton JH; Strouse JJ; Miller J; Paice JA; Veeramreddy P; Kavanagh PL; Wilkerson RG; Hughes R; Barnhart HX
    Acad Emerg Med; 2023 Dec; 30(12):1210-1222. PubMed ID: 37731093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electronic Health Record-Embedded Individualized Pain Plans for Emergency Department Treatment of Vaso-occlusive Episodes in Adults With Sickle Cell Disease: Protocol for a Preimplementation and Postimplementation Study.
    Luo L; King AA; Carroll Y; Baumann AA; Brambilla D; Carpenter CR; Colla J; Gibson RW; Gollan S; Hall G; Klesges L; Kutlar A; Lyon M; Melvin CL; Norell S; Mueller M; Potter MB; Richesson R; Richardson LD; Ryan G; Siewny L; Treadwell M; Zun L; Armstrong-Brown J; Cox L; Tanabe P
    JMIR Res Protoc; 2021 Apr; 10(4):e24818. PubMed ID: 33861209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Interrupted Time Series Analysis of the Dissemination of a Sickle Cell Vaso-Occlusive Episode Treatment Algorithm and a Case Management Referral Form for Individuals With Sickle Cell Disease in the Emergency Department.
    Bulgin D; Bonnabeau E; Alexander A; Frederick E; Rains G; Shah N; Young M; Tanabe P
    J Emerg Nurs; 2021 Jan; 47(1):40-49.e1. PubMed ID: 32826064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.